Oct 18, 2007 - Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that it has added a new diabetes drug targeting the sodium dependent glucose transporter type 2 (SGLT2) to its development pipeline. ISIS 388626, a generation 2.2 antisense drug that acts in the kidney to increase glucose excretion, complements Isis' existing pipeline of drugs in development for the treatment of diabetes, each of which act upon targets in the liver through distinct mechanisms to improve insulin sensitivity, reduce glucose production*, or affect other metabolic aspects of this complex disease... Isis' Press Release -
Friday, October 19, 2007
Isis, New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes
Oct 18, 2007 - Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that it has added a new diabetes drug targeting the sodium dependent glucose transporter type 2 (SGLT2) to its development pipeline. ISIS 388626, a generation 2.2 antisense drug that acts in the kidney to increase glucose excretion, complements Isis' existing pipeline of drugs in development for the treatment of diabetes, each of which act upon targets in the liver through distinct mechanisms to improve insulin sensitivity, reduce glucose production*, or affect other metabolic aspects of this complex disease... Isis' Press Release -
